Events

ICT H2020 Consortium Building Workshop
JUN
Wed
05
10:00 - 15:00

This was 6 years ago

Location

Permanent Representation of Lithuania to the EU 



Rue Belliard 41-43 



Brussels


Programmes
ICT

The Czech Liaison Office for Research Development and Innovation (CZELO), Lithuanian RDI Liaison Office (LINO) and the Slovak Liaison Office for Research and Development (SLORD) together with other associated Brussels based RTD liaison offices from EU member states and H2020 associated countries jointly organise a half-day Consortium building workshop around selected topics of the upcoming Horizon 2020 programme Information and Communication Technologies calls for 2020.

More information can be found here

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.